Christian Zwingelstein

Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis

Edward Abraham, Konrad Reinhart, Steven M. Opal et al. · JAMA · 2003 · 957 citations

Medicine, Pharmacology, Pharmacotherapy +15

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study

Edward Abraham, Konrad Reinhart, Petr Svoboda et al. · Critical Care Medicine · 2001 · 253 citations

Medicine, Pharmacology, Pharmacotherapy +16

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease

E. Schmitt, Meliana Riwanto, Vasan K. Sambandamurthy et al. · Angewandte Chemie International Edition · 2011 · 199 citations

Medicine, Molecular Biology, Pharmacology +6

Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia: A Randomized Trial

Richard G. Wunderink, Pierre-François Laterre, Bruno François et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 128 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement

Nicolas Guérard, Daniel Oder, Peter Nordbeck et al. · Clinical Pharmacology & Therapeutics · 2017 · 111 citations

Medicine, Pharmacokinetics, Pharmacology +13